BioPharma Company Licenses Technology from MD Anderson Cancer Center

Aug 13, 2010

Mercator Therapeutics also receives $2M in seed level financing

The agreement between Mercator and MD Anderson provides the start-up company with a broad portfolio of IP and rights to certain improvements to that portfolio. Mercator Therapeutics, based in Massachusetts, claims it is the first biopharmaceutical company to systematically use in vivo phage display technology for the development of revolutionary cancer drugs. Dr. Wadih Arap, Dr. Renata Pasqualini, and others at MD Anderson developed and discovered the technology used by Mercator. The seed funding investors were not disclosed.

↑ Back to TechConnect News™

---